Jim Cornall

Crawley, Crosshill

Writer, Photographer, Editor at Freelance

Host at Beyond Biotech - The Podcast from Labiotech

Founder and Publisher at Deeptech Digest

Featured in: Favicon

labiotech.eu Favicon

einnews.com Favicon

beveragedaily.com Favicon

nutraingredients.com Favicon

dairyreporter.com Favicon

organicinsider.com Favicon

deeptechdigest.com

Articles

From Danone to Muller: Why kefir is a big pull for big brands

1 month ago | dairyreporter.com | Jim Cornall

The kefir category has exploded in the past five years, going from niche to mainstream, as consumers focus their attention on natural foods with functional benefits. Having been confined to the ethnic dairy sections years ago, the cultured, low-lactose, probiotic-rich drink has a firm presence in the chilled dairy aisle today.
[Rebroadcast] How AI immune system mapping can boost drug discovery

Mar 7, 2025 | podcast.labiotech.eu | Jim Cornall

We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week!Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before.
The TCR-T cell therapies of tomorrow

Feb 28, 2025 | mynewsdesk.com | Jim Cornall

Do you work in the press or media? The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
The TCR-T cell therapies of tomorrow

Feb 28, 2025 | podcast.labiotech.eu | Jim Cornall

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1. The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date.
Can RNA drugs solve the obesity epidemic?

Feb 21, 2025 | podcast.labiotech.eu | Jim Cornall

Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment. Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss.
Reversing cancer mechanisms to fight back against solid tumors

Feb 14, 2025 | podcast.labiotech.eu | Jim Cornall

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance.
Targeting the dark genome to develop new therapies to fight obesity

Feb 7, 2025 | podcast.labiotech.eu | Jim Cornall

In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark GenomeThis week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics.
Can Tumor Activated Therapy kill solid tumors?

Jan 31, 2025 | podcast.labiotech.eu | Jim Cornall

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution.
Gen AI supercharges research into safe methane inhibitors for cattle

Jan 27, 2025 | dairyreporter.com | Jim Cornall

US-based scientists have uncovered a way to fast-track research into non-toxic methane inhibition in cattle by deploying artificial intelligence and machine learning. The cohort – made up of academics from the Livestock Nutrient Management Research Unit of the USDA-ARS, the Iowa State University and the Kansas State University Department of Animal Science and Industry – leveraged the technology to find which among thousands of molecules in the cow’s body could act as natural methane inhibitors.
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed

Jan 24, 2025 | podcast.labiotech.eu | Jim Cornall

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.